-
Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study2024 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Blood disorders and treatments
Antonio Maria Risitano, Simona Iacobelli, Austin Gladston Kulasekararaj, Marleen van Os, Morag Griffin, Constantijn J.M. Halkes, +43 more
1citations -
Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
Brendan Paul Hodkinson, Ashwini Kumar, Sheri Skerget, Gary E. Mason, Elizabeth Shearin, Hein Ludlage, +26 more
1citations -
The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial
Régis Peffault de Latour, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yutaka Ueda, Carlos de Castro, Samopriyo Maitra, +3 more
1citations -
T-cell clones of uncertain significance are prevalent in cutaneous T-cell lymphomas2025 Blood conference-abstract Medicine Cutaneous lymphoproliferative disorders research Open access
Safa Najidh, Joseph C. Cleveland, Armando N. Bastidas Torres, Alexa C. Kwang, George E. Durán, Yonatan A. Cooper, +4 more
1citations -
Distinct morphological features of malignant cells in large B-cell lymphoma identified by soft-segmentation in imaging-based spatial proteomics2025 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Cell Image Analysis Techniques Open access
Troy Noordenbos, Marieke E. Ijsselsteijn, Noel de Miranda, Joost S.P. Vermaat, Mohammad Shahrokh Esfahani
1citations -
Transformed FL shows improved survival after CAR T-cell therapy compared to de novo LBCL, but early transformation (<12 months) defines a poor-risk subgroup: Results from a nationwide cohort
Hilde T. van der Galiën, Pim G. N. J. Mutsaers, Margot Jak, Marjolein van der Poel, Marije T. Nijk, Kees Meijer, +13 more
1citations -
Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)
Frank Stegelmann, Lino Lars Teichmann, Florian Heinrich Heidel, Carl C. Crodel, Thomas Ernst, Sebastian Kreil, +11 more
0citations